Cytotoxic drugs or cytostatics (cytotoxic chemotherapy) are agents that are used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms. Increasing usage and approval of cytotoxic drugs are major factors that are expected to drive the cytotoxic drugs market growth. These drugs are also used for their immunosuppressive effect in the treatment of auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection.
To get a detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/2533
Global Cytotoxic Drugs Market: Drivers
The cytotoxic drugs market is expected to witness significant growth over the forecast period, owing to increasing incidence of cancer globally. For instance, according to the World Health Organization’s (WHO) 2018 report, around 9.6 million deaths were recorded due to cancer and around 18.1 million new cases of cancer were diagnosed in 2018, across the globe.
Furthermore, increasing number of cytotoxic drug approvals is expected to boost the market growth over the forecast period. For instance, in November 2018, the U.S. FDA approved Pfizer’s DAURISMO (glasdegib) in the U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option. Other potential factor that contributes to cytotoxic drugs market revenue growth include increasing therapeutic area of cytotoxic drugs in auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection because of its immunosuppressive or anti-proliferative effects.
Global Cytotoxic Drugs Market: Restraints
The major restraining factor for the cytotoxic drugs market growth include adverse side effects shown by consumption of cytotoxic drugs such as nausea and vomiting, severe diarrhea, and damage to bone marrow. Cytotoxic drugs can be toxic to other organ systems and can lead to conditions such as gastrointestinal toxicity, neurotoxicity renal toxicity, and cardiovascular toxicity. For instance, according to the NHS Lothian Joint Formulary, drugs such as fluorouracil, doxorubicin, and oral capecitabine may cause severe stomatitis, diarrhea, and coronary spasm mimicking angina. Moreover, systemic anti-cancer therapy (SACT) drugs increase the risk of thromboembolic disease eventually restraining the cytotoxic drugs market growth.
Get Discount For First Time Buyers
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2533
Global Cytotoxic Drugs Market: Regional Analysis
North America is expected to hold dominant position in the cytotoxic drugs market over the forecast period, owing to increasing awareness and availability of wide range of cytotoxic drugs in the region. For instance, according to a study published in the National Center for Biotechnology Information (NCBI) in 2017, the U.S. Food and Drug Administration approved 61 cytotoxic drugs for cancer, which help in increasing the survival rates of cancer patients.
Asia Pacific cytotoxic drugs market is expected to witness significant growth, owing to large patient base and increasing healthcare insurance schemes in the region. For instance, in 2018, the Government of India launched Pradhan Mantri Jan Arogya Yojana (PMJAY) to provide health insurance worth US$ 7,124.54 to over 100 million families, annually.
Global Cytotoxic Drugs Market: Competitive Landscape
Key players operating in the global cytotoxic drugs market include Eli Lilly and Company, Sanofi S.A., F. Hoffmann-La Roche Ltd, Pfizer Inc., Celgene Corporation, Amgen Inc., Novartis AG Merck and Co., Johnson and Johnson, and GlaxoSmithKline Plc.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2533
Global Cytotoxic Drugs Market: Taxonomy
The global cytotoxic drugs market is segmented on the basis of drug type, application, route of administration, distribution channel, and region.
By Drug Type
- Alkylating Agents
- Cytotoxic Antibiotics
- Antimetabolites
- Vinca Alkaloids and Etoposide
- Antineoplastic Drugs
By Application
- Oncology
- Auto-immune Disorders
- Transplantation
By Route of Administration
- Oral
- Subcutaneous/Intramuscular
- Intravenous
- Intrathecal
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837